Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

Forum Transenterix geopend

344 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 18 »» | Laatste | Omlaag ↓
  5. forum rang 5 RW1963 3 juni 2019 19:35

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 06 apr 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9932

    •    Aantal posts: 6.301

    Persoonlijk hecht ik er weinig waarde aan. Maar Marktgevoel tipt dit aandeel deze maand wel.
  6. [verwijderd] 5 juni 2019 11:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    RW1963 schreef op 3 juni 2019 19:35:

    Persoonlijk hecht ik er weinig waarde aan. Maar Marktgevoel tipt dit aandeel deze maand wel.
    Alles is meegenomen.
  10. [verwijderd] 8 augustus 2019 14:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zo zeg, deze gaat lekker door het putje vanweg de slechte Q2 cijfers!

    BC Capital downgraded the stock from Outperform to Sector Perform and lowered its price target from $3 to $1 per share

    RIP
  11. forum rang 10 DeZwarteRidder 8 augustus 2019 16:14

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 26 apr 2024

    • Aanbevelingen

      Ontvangen: 20866

      Gegeven: 9471

    •    Aantal posts: 96.794

    quote:

    DeZwarteRidder schreef op 13 oktober 2018 14:33:

    Dit aandeel is belachelijk duur en loopt lichtjaren vooruit op winst die misschien nooit gemaakt zal worden.
    OoooJeee.....!!!

    Een koersdoel van 1 $.....!!!

    Wie had dat nou verwacht....????
  12. forum rang 10 DeZwarteRidder 9 augustus 2019 15:50

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 26 apr 2024

    • Aanbevelingen

      Ontvangen: 20866

      Gegeven: 9471

    •    Aantal posts: 96.794


    TransEnterix, Inc. Reports Operating and Financial Results for the Second Quarter 2019
    August 7, 2019 at 4:05 PM EDT

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug. 7, 2019-- TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2019.

    Recent Highlights

    Total revenue of $3.6 million in the second quarter of 2019
    Received Japanese regulatory approval of the Senhance® Surgical System
    Received broad Japanese reimbursement for 98 different procedures, effective July 31, 2019
    AutoLap asset sale and equity sale to bring in a total of $47 million

    “While we were disappointed with our system sales in the quarter, we are encouraged by our operational accomplishments including the monetization of the AutoLap assets and achievement of Japanese regulatory approval and broad reimbursement well ahead of our expectations,” said Todd M. Pope, President, and CEO of TransEnterix. “We are focused on improving commercial execution to drive global system sales in the second half of the year.”

    Commercial and Clinical Update

    In the quarter ended June 30, 2019, the Company sold one Senhance® System, in the EMEA region to an end user hospital.

    On May 28, 2019, the Company announced that it received Japanese regulatory approval for the Senhance Surgical System. The Senhance Surgical System was approved by the Ministry of Health, Labor and Welfare (MHLW) for use in laparoscopy for general surgery, gynecology, and urology.

    On August 1, 2019, the Company announced that the MHLW expert review panel provided reimbursement for procedures performed with the Senhance Surgical System. The reimbursement, which became effective on July 31, 2019, applies to 98 benign and malignant laparoscopic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1.

    AutoLap Asset Sale

    On July 10, the Company announced the sale of certain AutoLap® image-based laparoscope positioning system (AutoLap) product and intellectual property assets to Great Belief International Limited (GBIL). The total proceeds to be paid to the Company for these assets is $17 million. In addition, GBIL is making an equity investment of $30.0 million in TransEnterix common stock at $2.00 per share. As a part of the sale agreement, the Company retains ownership of the broader intellectual property portfolio it acquired from M.S.T. - Medical Surgery Technologies in October 2018, and will enter into a cross-license agreement with GBIL under which it gains a license to use the AutoLap-related IP sold, and grants GBIL a non-exclusive license to use additional IP in connection with the AutoLap.

    Second Quarter Financial Highlights

    For the three months ended June 30, 2019, the Company reported revenue of $3.6 million as compared to revenue of $6.4 million in the three months ended June 30, 2018. Revenue in the second quarter of 2019 included $2.7 million in system sales, $560 thousand in instruments and accessories, and $342 thousand in services. The $2.7 million in system sales revenue includes the recognition of $1.3 million from a system sold in 2017 for which revenue was deferred until its first clinical use, which occurred in the second quarter.

    For the three months ended June 30, 2019, total net operating expenses were $22.2 million, as compared to $18.5 million in the three months ended June 30, 2018.

    For the three months ended June 30, 2019, net loss was $20.2 million, or $0.09 per basic share, as compared to a net loss of $34.2 million, or $0.17 per basic share, in the three months ended June 30, 2018.

    For the three months ended June 30, 2019, adjusted net loss was $19.2 million, or $0.09 per basic share, as compared to an adjusted net loss of $11.7 million, or $0.06 per basic share in the three months ended June 30, 2018, after adjusting for the following charges: change in fair value of warrant liabilities, amortization of intangible assets, change in fair value of contingent consideration, loss on debt extinguishment, acquisition-related costs and the loss (gain) on the sale of the SurgiBot assets. Adjusted net loss is a non-GAAP measure. See the reconciliation to GAAP below.

    The Company had cash and cash equivalents, restricted cash and short term investments of approximately $34.0 million as of June 30, 2019. The Company believes that existing cash and short term investments and the expected proceeds from the AutoLap transaction are sufficient to support the business into mid-2020.

    Conference Call

    TransEnterix, Inc. will host a conference call on Wednesday, August 7, 2019, at 4:30 p.m. ET to discuss its second quarter 2019 operating and financial results. To listen to the conference call on your telephone, please dial (844) 804-5261 for domestic callers or (612) 979-9885 for international callers and reference conference ID 4293967 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link ir.transenterix.com/events.cfm. The replay will be available on the Company's website.

    About TransEnterix

    TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, and select other countries. For more information, visit www.transenterix.com.
  14. [verwijderd] 6 september 2019 07:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Transenterix56 schreef op 10 mei 2019 21:04:

    Zuid-Duitsland + geheel nieuwe techniek, meer kan ik echt niet zeggen!!!
    Weet je inmiddels al wat meer?
  17. [verwijderd] 9 september 2019 07:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Transenterix56 schreef op 16 april 2019 11:23:

    Heeft iets langer geduurd als gewenst maar heb informatie ontvangen inmiddels. Ik kan niet exact aangeven wat de ontwikkelingen zijn maar we kunnen als longers rustig blijven zitten. Zelfs nog iets bijkopen als mogelijk is. Ik kijk relaxed de toekomst tegen moet. Als alles gerealiseerd wordt zijn er spectaculaire ontwikkelingen te verwachten!!!!
    Licht eindelijk eens een tipje van de sluier op!!!!
  18. forum rang 10 DeZwarteRidder 9 september 2019 07:27

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 26 apr 2024

    • Aanbevelingen

      Ontvangen: 20866

      Gegeven: 9471

    •    Aantal posts: 96.794

    quote:

    veer62 schreef op 6 september 2019 12:42:

    Dezwarteridder wil jij je oog laten vallen op kbsf.alvast bedankt
    Ik heb geen idee wat dat is.
344 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 18 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.311
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.895
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.342
Aedifica 2 829
Aegon 3.257 320.052
AFC Ajax 537 7.018
Affimed NV 2 5.752
ageas 5.843 109.777
Agfa-Gevaert 13 1.856
Ahold 3.536 73.980
Air France - KLM 1.024 34.310
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.769
Alfen 12 16.261
Allfunds Group 3 1.190
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 332
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.249
AMG 965 125.684
AMS 3 73
Amsterdam Commodities 303 6.519
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.111
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.598
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.106
Aroundtown SA 1 176
Arrowhead Research 5 9.264
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.675
ASML 1.762 76.890
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.650
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.664

Macro & Bedrijfsagenda

  1. 29 april

    1. NL producentenvertrouwen april
    2. Philips Q1-cijfers
    3. Umicore Q1-cijfers
    4. Proximus Q1-cijfers
    5. Fra BBP eerste kwartaal (voorlopig)
    6. AkzoNobel €1,54-ex-dividend
    7. Besi €2,15 ex-dividend
    8. Fugro €0,40 ex-dividend
    9. Heineken €1,04 ex-dividend
    10. Vastned €1,28 ex-dividend
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda